Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Abstract The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis‐4 index (FIB‐4), and NAFLD fibrosis score (NFS) were ass...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Kaohsiung Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/kjm2.12804 |
| _version_ | 1797216991513149440 |
|---|---|
| author | Chung‐Feng Huang Po‐Cheng Liang Chih‐Wen Wang Tyng‐Yuan Jang Po‐Yao Hsu Pei‐Chien Tsai Yu‐Ju Wei Ming‐Lun Yeh Ming‐Yen Hsieh Yi‐Hung Lin Chao‐Kuan Huang Chia‐Yen Dai Jee‐Fu Huang Wan‐Long Chuang Ming‐Lung Yu |
| author_facet | Chung‐Feng Huang Po‐Cheng Liang Chih‐Wen Wang Tyng‐Yuan Jang Po‐Yao Hsu Pei‐Chien Tsai Yu‐Ju Wei Ming‐Lun Yeh Ming‐Yen Hsieh Yi‐Hung Lin Chao‐Kuan Huang Chia‐Yen Dai Jee‐Fu Huang Wan‐Long Chuang Ming‐Lung Yu |
| author_sort | Chung‐Feng Huang |
| collection | DOAJ |
| description | Abstract The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis‐4 index (FIB‐4), and NAFLD fibrosis score (NFS) were assessed in 871 MAFLD patients who received elastography in a viral hepatitis‐endemic area. The area under the receiver operating characteristic (AUROC) curve increased substantially with increasing fibrotic stage across the three biomarkers. APRI (AUROC range 0.73–0.80) and FIB‐4 (AUROC range 0.66–0.82) performed better than NFS (AUROC range 0.63–0.75). When patients were divided into viral and non‐viral MAFLD groups, a better AUROC of APRI (range 0.76–0.80) and FIB‐4 (range 0.68–0.78) than NFS (range 0.62–70) existed only in viral MALFD but not in non‐viral MAFLD. Regarding the NFS, the AUROC was higher in non‐viral MAFLD (range 0.69–0.86) and outperformed viral MAFLD at all fibrotic stages. The accuracy in predicting liver fibrosis increased with the advancement of liver disease for the three biomarkers. NFS exerted better diagnostic accuracy in non‐viral than in viral MAFLD patients across different fibrotic stages. The best accuracy was 91.1% using the cutoff value of −9.98 for the NFS in predicting liver cirrhosis in non‐viral MAFLD patients. The APRI and FIB‐4 performed better than the NFS in predicting liver fibrosis in MAFLD as a whole. The suboptimal performance and accuracy of the NFS existed only in viral MAFLD patients. Caution should be taken when assessing the NFS in MAFLD patients with viral hepatitis. |
| first_indexed | 2024-04-24T11:54:45Z |
| format | Article |
| id | doaj.art-b2bf93ff14fb4706a81194ac1a7f56e1 |
| institution | Directory Open Access Journal |
| issn | 1607-551X 2410-8650 |
| language | English |
| last_indexed | 2024-04-24T11:54:45Z |
| publishDate | 2024-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Kaohsiung Journal of Medical Sciences |
| spelling | doaj.art-b2bf93ff14fb4706a81194ac1a7f56e12024-04-09T05:56:38ZengWileyKaohsiung Journal of Medical Sciences1607-551X2410-86502024-04-0140437438310.1002/kjm2.12804Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitisChung‐Feng Huang0Po‐Cheng Liang1Chih‐Wen Wang2Tyng‐Yuan Jang3Po‐Yao Hsu4Pei‐Chien Tsai5Yu‐Ju Wei6Ming‐Lun Yeh7Ming‐Yen Hsieh8Yi‐Hung Lin9Chao‐Kuan Huang10Chia‐Yen Dai11Jee‐Fu Huang12Wan‐Long Chuang13Ming‐Lung Yu14Hepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanHepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung TaiwanAbstract The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis‐4 index (FIB‐4), and NAFLD fibrosis score (NFS) were assessed in 871 MAFLD patients who received elastography in a viral hepatitis‐endemic area. The area under the receiver operating characteristic (AUROC) curve increased substantially with increasing fibrotic stage across the three biomarkers. APRI (AUROC range 0.73–0.80) and FIB‐4 (AUROC range 0.66–0.82) performed better than NFS (AUROC range 0.63–0.75). When patients were divided into viral and non‐viral MAFLD groups, a better AUROC of APRI (range 0.76–0.80) and FIB‐4 (range 0.68–0.78) than NFS (range 0.62–70) existed only in viral MALFD but not in non‐viral MAFLD. Regarding the NFS, the AUROC was higher in non‐viral MAFLD (range 0.69–0.86) and outperformed viral MAFLD at all fibrotic stages. The accuracy in predicting liver fibrosis increased with the advancement of liver disease for the three biomarkers. NFS exerted better diagnostic accuracy in non‐viral than in viral MAFLD patients across different fibrotic stages. The best accuracy was 91.1% using the cutoff value of −9.98 for the NFS in predicting liver cirrhosis in non‐viral MAFLD patients. The APRI and FIB‐4 performed better than the NFS in predicting liver fibrosis in MAFLD as a whole. The suboptimal performance and accuracy of the NFS existed only in viral MAFLD patients. Caution should be taken when assessing the NFS in MAFLD patients with viral hepatitis.https://doi.org/10.1002/kjm2.12804APRIFIB4fibrosisMAFLDNFS |
| spellingShingle | Chung‐Feng Huang Po‐Cheng Liang Chih‐Wen Wang Tyng‐Yuan Jang Po‐Yao Hsu Pei‐Chien Tsai Yu‐Ju Wei Ming‐Lun Yeh Ming‐Yen Hsieh Yi‐Hung Lin Chao‐Kuan Huang Chia‐Yen Dai Jee‐Fu Huang Wan‐Long Chuang Ming‐Lung Yu Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis Kaohsiung Journal of Medical Sciences APRI FIB4 fibrosis MAFLD NFS |
| title | Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis |
| title_full | Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis |
| title_fullStr | Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis |
| title_full_unstemmed | Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis |
| title_short | Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis |
| title_sort | performance of noninvasive seromarkers in predicting liver fibrosis among mafld patients with or without viral hepatitis |
| topic | APRI FIB4 fibrosis MAFLD NFS |
| url | https://doi.org/10.1002/kjm2.12804 |
| work_keys_str_mv | AT chungfenghuang performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT pochengliang performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT chihwenwang performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT tyngyuanjang performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT poyaohsu performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT peichientsai performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT yujuwei performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT minglunyeh performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT mingyenhsieh performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT yihunglin performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT chaokuanhuang performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT chiayendai performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT jeefuhuang performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT wanlongchuang performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis AT minglungyu performanceofnoninvasiveseromarkersinpredictingliverfibrosisamongmafldpatientswithorwithoutviralhepatitis |